Description
CJC-1295 (no DAC) & Hexarelin
CJC-1295 (no DAC) and Hexarelin are synthetic research peptides that have been studied for their effects on growth hormone (GH) regulation through distinct pituitary receptor systems. Both compounds act on anterior pituitary cells but do so via different molecular targets, which may result in complementary stimulation of GH synthesis and release. Because of these separate but converging pathways, researchers have suggested that their combined use could produce enhanced pituitary activity compared to either agent alone.
Chemical Information
Alternative names
- CJC-1295 (no DAC): Modified GRF 1-29
- Hexarelin: Examorelin, P-23905, MF-6003
Molecular formula
- CJC-1295 (no DAC): C152H252N44O42
- Hexarelin: C47H58N12O6
Research and Mechanisms
CJC-1295 (no DAC) and GHRH receptor activity
CJC-1295 (no DAC) is considered a modified fragment of growth hormone-releasing hormone (GHRH), corresponding to the first 29 amino acids of the native 44–amino acid hormone. It is believed to retain strong affinity for GHRH receptors on pituitary somatotrophs.
Structural modifications at positions 2, 8, 15, and 27 are thought to improve stability and resistance to enzymatic degradation. These substitutions may also prolong receptor interaction and extend biological activity. Despite these changes, the downstream signaling is believed to mirror endogenous GHRH, primarily involving activation of adenylate cyclase, increased cyclic AMP (cAMP), and subsequent protein kinase A (PKA) activation. This cascade promotes calcium influx and facilitates the release of stored growth hormone, while also potentially increasing GH gene expression.
Research by Alba et al. suggests that CJC-1295 (no DAC) may increase pituitary GH mRNA and total RNA levels, indicating possible stimulation of somatotroph activity and gene expression linked to GH production.
Hexarelin and GHS-R1a signaling
Hexarelin is classified as a growth hormone secretagogue (GHS) rather than a GHRH analog. It binds primarily to the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.
Activation of this receptor triggers phospholipase C (PLC) signaling, leading to the formation of IP₃ and DAG. IP₃ promotes intracellular calcium release, while DAG activates protein kinase C (PKC). The combined increase in intracellular calcium and PKC activity supports vesicle fusion and growth hormone release from somatotroph cells.
Unlike GHRH-based peptides, Hexarelin operates through a distinct but converging intracellular pathway that ultimately leads to GH secretion.
Effects on growth hormone secretion
Experimental studies indicate that CJC-1295 (no DAC) may significantly increase GH output, particularly within the first hours of exposure. Khorram et al. report multi-fold increases in integrated GH secretion and a corresponding rise in IGF-1 levels after sustained exposure.
Hexarelin has also demonstrated strong GH-releasing activity in experimental models. Imbimbo et al. observed rapid and substantial GH elevation following administration, with peak levels occurring within approximately 30–40 minutes before gradually returning toward baseline. Other endocrine markers such as LH, FSH, and TSH were reported as largely unaffected in these settings.
Synergistic potential
While direct studies on the combination of CJC-1295 (no DAC) and Hexarelin are limited, related research using GHRH analogs and GHS compounds provides insight into their potential interaction.
Studies by Arvat et al. show that simultaneous activation of GHRH receptors and GHS-R1a can produce greater GH secretion than either pathway alone. In experimental settings, combined stimulation resulted in GH output exceeding the sum of individual responses, suggesting true synergistic effects at the pituitary level.
This supports the hypothesis that pairing a GHRH analog such as CJC-1295 (no DAC) with a GHS like Hexarelin may amplify pulsatile GH release by engaging complementary signaling systems.
This peptide combination is described for research and laboratory use only.
Reviews
There are no reviews yet.